Big news: Cell Source ( $CLCS ) Presents Potential
Post# of 37283
https://finance.yahoo.com/news/cell-source-pr...00616.html
The research showcased how the company's proprietary Veto Cell technology can overcome one of the most critical barriers in allogeneic cell therapy - natural killer (NK) cell-mediated rejection. This innovation brings the field closer to realizing off-the-shelf CAR-T therapies, which can be safer, less costly and more scalable than existing allogeneic CAR-T.